"Aniline Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the aminobenzene structure.
| Descriptor ID |
D000814
|
| MeSH Number(s) |
D02.092.146
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aniline Compounds".
Below are MeSH descriptors whose meaning is more specific than "Aniline Compounds".
This graph shows the total number of publications written about "Aniline Compounds" by people in this website by year, and whether "Aniline Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 2 | 0 | 2 |
| 2026 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aniline Compounds" by people in Profiles.
-
Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia. Nat Cell Biol. 2026 Aug; 28(8):1715-1727.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation. Clin Pharmacokinet. 2026 Sep; 65(9):1389-1403.
-
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma. Nat Commun. 2026 Jun 26; 17(1).
-
Osimertinib activates a TGF-?2-dependent secretory program that drives lung adenocarcinoma progression. J Clin Invest. 2026 02 02; 136(3).
-
Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells. Exp Gerontol. 2025 Nov; 211:112885.
-
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib. JCO Precis Oncol. 2025 May; 9:e2500047.
-
Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis. J Control Release. 2024 06; 370:110-123.
-
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 04; 8:e2300454.
-
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 03 01; 42(7):821-831.